This study demonstrated that AS/BJO-NEs inhibited the proliferation, migration, invasion and EMT process of OSCC by down-regulating CDK1 and subsequently reducing MTFR2 expression, exerting anti-tumor effects and providing new possibilities and a theoretical foundation for OSCC treatment. The gene discussed is MTFR2; the disease is neoplasm.